Status:

RECRUITING

The PREDICT Registry:

Lead Sponsor:

PreludeDx

Conditions:

DCIS

Eligibility:

FEMALE

30-85 years

Brief Summary

This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criter...

Detailed Description

After a diagnosis of DCIS, the most representative tissue block (or 10 sections mounted on charged slides cut at 3-4 microns) will be sent to PreludeDx for DCISionRT. The most representative specimen ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
  • Patient must have the DCISionRT test ordered during routine patient care.
  • Patient must be eligible for or have recently completed breast conserving surgery.
  • Patient must be eligible to receive radiation and/or systemic treatment.
  • Patient must be 30 to 85 years old.
  • Patient must have tumor size of less than 6 cm.
  • Patient must have been diagnosed with DCIS within 120 days of consent.
  • Exclusion criteria
  • Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing.
  • Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget\'s disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast.
  • Patient has been surgically treated with an ipsilateral mastectomy for primary DCIS.
  • Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer.
  • Patient has a prior history of in-field radiation in the ipsilateral breast.
  • Patient has had prior systemic endocrine or chemotherapy prior to testing.
  • Patient is pregnant.

Exclusion

    Key Trial Info

    Start Date :

    February 27 2018

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2035

    Estimated Enrollment :

    3000 Patients enrolled

    Trial Details

    Trial ID

    NCT03448926

    Start Date

    February 27 2018

    End Date

    December 1 2035

    Last Update

    September 19 2024

    Active Locations (15)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (15 locations)

    1

    Arizona Center for Cancer Care

    Phoenix, Arizona, United States, 85027

    2

    Sutter Institute for Medical Research

    Sacramento, California, United States, 95816

    3

    Mills-Peninsula Medical Center

    San Mateo, California, United States, 94019

    4

    University of Colorado Denver

    Aurora, Colorado, United States, 80045